PuSH - Publication Server of Helmholtz Zentrum München

Yazgili, A.S. ; Ebstein, F.* ; Meiners, S.*

The proteasome activator PA200/PSME4: An emerging new player in health and disease.

Biomolecules 12:1150 (2022)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Corresponding Author
Keywords Pa200 ; Psme4 ; Proteasome
ISSN (print) / ISBN 2218-273X
e-ISSN 2218-273X
Journal Biomolecules
Quellenangaben Volume: 12, Issue: 8, Pages: , Article Number: 1150 Supplement: ,
Publisher MDPI
Publishing Place Basel
Non-patent literature Publications
Reviewing status Peer reviewed
Grants Bundesministerium für Bildung und Forschung
German Ministry of Research